A Study of Neoadjuvant SHR6390 in Combination With Anastrozole, Pyrotinib, and Trastuzumab in Patients With ER+/HER2+ Breast Cancer.

Conditions:   Breast Cancer;   HER2-positive Breast Cancer;   ER-positive Breast Cancer Interventions:   Drug: SHR6390;   Drug: Anastrozole;   Drug: Pyrotinib;   Drug: Trastuzumab Sponsors:   Ruijin Hospital;   Jiangsu HengRui Medicine Co., Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials